News & Events

News

Our latest Press Releases

Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target

Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

More News

EVENTS

Meet Tubulis live

More Events